MAPT and supranuclear palsy, progressive, 1: p‐Tau pathology has previously been extensively characterized in post‐mortem tissue from PSP patients using the AT8 antibody (Goedert et al., 1995; Malia et al., 2016; Pikkarainen et al., 2010; Williams et al., 2007).